Cardiotoxicity Related to Long‐Term Trastuzumab Therapy in Metastatic Breast Cancer: The Potential Role of Treatment Duration and Cardiac Risk Factors

Publisher： John Wiley & Sons Inc

E-ISSN： 1524-4741|21|3|318-321

ISSN： 1075-122x

Source： THE BREAST JOURNAL, Vol.21, Iss.3, 2015-05, pp. : 318-321

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer

By  

CANCER, Vol. 119, Iss. 22, 2013-11 ,pp. : 3943-3951

John Wiley & Sons Inc

Access to resources Recommend Favorite

Trastuzumab Single-Drug Therapy after Failure of Cytotoxic Treatment for Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 33, Iss. 8-9, 2010-07 ,pp. : 425-430

Karger

Access to resources Recommend Favorite

Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer

By  

Case Reports in Oncology, Vol. 5, Iss. 3, 2012-12 ,pp. : 687-692

Karger

Access to resources Recommend Favorite

Cardiotoxicity and Cancer Therapy: Treatment-Related Cardiac Morbidity in Patients Presenting with Symptoms Suggestive of Heart or Lung Disease

By  

Oncology, Vol. 85, Iss. 3, 2013-08 ,pp. : 137-144

Karger

Access to resources Recommend Favorite

Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 33, Iss. 8-9, 2010-07 ,pp. : 420-421

Karger

Access to resources Recommend Favorite